Is Entero Healthcar overvalued or undervalued?

As of 11 September 2025, Entero Healthcare's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as overvalued based on its high valuation ratios, including a PE ratio of 50.15, an EV to EBITDA of 27.22, and a PEG ratio of 0.35. These figures suggest that Entero Healthcare is trading at a premium compared to its peers. In comparison, TCS and HCL Technologies, both rated as attractive, have significantly lower PE ratios of 22.94 and 23.46, respectively, which highlights the disparity in valuation. Additionally, Entero's ROCE stands at 7.86% and ROE at 5.50%, which are relatively modest compared to the high multiples it commands. The company's stock has underperformed against the Sensex, with a year-to-date return of -16.17% compared to the Sensex's 4.36%, reinforcing the notion that Entero Healthcare is overvalued in the current market environment.